2026 Q2 - tulosraportti
46 päivää sitten
‧30 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 614 | - | - | ||
| 1 099 | - | - | ||
| 1 152 | - | - | ||
| 4 000 | - | - | ||
| 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 19.2. | ||
Liiketoimintakatsaus 16.1. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 t sittenWhy is it plummeting today?
I think there is a fear of additional NE after today's webcast. Both CEO and CFO became very defensive when questions came up about how Glioblastoma studies would be financed. https://oncopeptides.com/press-releases/invitation-to-oncopeptides-investor-webcast-following-positive-glioblastoma-data/
·6 t sittenMay I please reiterate that one gets extra lifespan when other treatment options have ended. Oncopeptides has achieved an important regulatory breakthrough after EMA's expert committee in September 2026 recommended expanding the use of Melflufen (Pepaxti) to an earlier line of treatment in relapsed myeloma. According to the company, the expansion could potentially double the European patient group and thereby create the basis for significant revenue growth. Melflufen has documented anti-tumor effect, and the OCEAN study showed a median progression-free survival of 6.8 months compared to 4.9 months with pomalidomide. However, the study did not show an overall survival benefit, which continues to be a significant clinical limitation.
·1 päivä sittenThere are significant doubts and challenges surrounding melflufen in solid tumors. Although the latest results for brain tumors (glioblastoma) represent an important scientific advance, the medical community is generally cautious. The main doubts and challenges can be divided into three areas: 1. Historically weak efficacy in clinical studies The biggest doubt is based on the fact that melflufen has already been tested in patients with advanced solid tumors (such as lung cancer and ovarian cancer) in a phase I/IIa study. The result there was very modest, as practically no tumors shrank. This has created widespread skepticism about using the drug as a broad treatment for common solid tumors. 2. Side damage to the bone marrow (Hematological toxicity) Melflufen is a so-called Peptide-Drug Conjugate (PDC) designed to seek out cells with high aminopeptidase levels (which tumor cells have). The problem is that melflufen in clinical studies has proven to be very tough on the bone marrow, leading to severe shortages of platelets (thrombocytopenia) and white blood cells (neutropenia). * The doubt: For melflufen to affect a solid tumor, high doses are often required. Physicians worry that the doses needed to actually shrink a solid tumor may cause such severe blood side effects that the patient cannot tolerate the treatment. 3. "Proof of Concept" in humans is required for glioblastoma The new successes from the INSULA study prove that melflufen crosses into the brain and reaches the tumor (which is a huge step). But the drug being present in the tumor is not the same as it automatically curing or prolonging the lives of patients. Experts emphasize that we are still only at an early stage, and there is doubt (or rather, scientific uncertainty) as to whether the concentration is high enough to provide a long-lasting clinical effect against such an aggressive form of cancer as glioblastoma. The history haunts us (the OCEAN study in the US)
·2 päivää sittenI am down -97 percent on this stock 🥶
I identified an entry point at the red dashed line five trading days ago, and bought 40000 shares this morning at 2.03. Have captured pretty much the entire day's upward move, corresponding to almost +45%, just saying it 😂😂
·2 päivää sittenHere we go, we should probably reach 10 kr if the flexibility process handling is fully met and they get a solid hit to eventually gain traction in the US via FDA approval.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 580 188 | 25 580 188 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 580 188 | 25 580 188 | 0 | 0 |
2026 Q2 - tulosraportti
46 päivää sitten
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenWhy is it plummeting today?I think there is a fear of additional NE after today's webcast. Both CEO and CFO became very defensive when questions came up about how Glioblastoma studies would be financed. https://oncopeptides.com/press-releases/invitation-to-oncopeptides-investor-webcast-following-positive-glioblastoma-data/
- ·6 t sittenMay I please reiterate that one gets extra lifespan when other treatment options have ended. Oncopeptides has achieved an important regulatory breakthrough after EMA's expert committee in September 2026 recommended expanding the use of Melflufen (Pepaxti) to an earlier line of treatment in relapsed myeloma. According to the company, the expansion could potentially double the European patient group and thereby create the basis for significant revenue growth. Melflufen has documented anti-tumor effect, and the OCEAN study showed a median progression-free survival of 6.8 months compared to 4.9 months with pomalidomide. However, the study did not show an overall survival benefit, which continues to be a significant clinical limitation.
- ·1 päivä sittenThere are significant doubts and challenges surrounding melflufen in solid tumors. Although the latest results for brain tumors (glioblastoma) represent an important scientific advance, the medical community is generally cautious. The main doubts and challenges can be divided into three areas: 1. Historically weak efficacy in clinical studies The biggest doubt is based on the fact that melflufen has already been tested in patients with advanced solid tumors (such as lung cancer and ovarian cancer) in a phase I/IIa study. The result there was very modest, as practically no tumors shrank. This has created widespread skepticism about using the drug as a broad treatment for common solid tumors. 2. Side damage to the bone marrow (Hematological toxicity) Melflufen is a so-called Peptide-Drug Conjugate (PDC) designed to seek out cells with high aminopeptidase levels (which tumor cells have). The problem is that melflufen in clinical studies has proven to be very tough on the bone marrow, leading to severe shortages of platelets (thrombocytopenia) and white blood cells (neutropenia). * The doubt: For melflufen to affect a solid tumor, high doses are often required. Physicians worry that the doses needed to actually shrink a solid tumor may cause such severe blood side effects that the patient cannot tolerate the treatment. 3. "Proof of Concept" in humans is required for glioblastoma The new successes from the INSULA study prove that melflufen crosses into the brain and reaches the tumor (which is a huge step). But the drug being present in the tumor is not the same as it automatically curing or prolonging the lives of patients. Experts emphasize that we are still only at an early stage, and there is doubt (or rather, scientific uncertainty) as to whether the concentration is high enough to provide a long-lasting clinical effect against such an aggressive form of cancer as glioblastoma. The history haunts us (the OCEAN study in the US)
- ·2 päivää sittenI am down -97 percent on this stock 🥶I identified an entry point at the red dashed line five trading days ago, and bought 40000 shares this morning at 2.03. Have captured pretty much the entire day's upward move, corresponding to almost +45%, just saying it 😂😂
- ·2 päivää sittenHere we go, we should probably reach 10 kr if the flexibility process handling is fully met and they get a solid hit to eventually gain traction in the US via FDA approval.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 614 | - | - | ||
| 1 099 | - | - | ||
| 1 152 | - | - | ||
| 4 000 | - | - | ||
| 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 19.2. | ||
Liiketoimintakatsaus 16.1. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 580 188 | 25 580 188 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 580 188 | 25 580 188 | 0 | 0 |
2026 Q2 - tulosraportti
46 päivää sitten
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 19.2. | ||
Liiketoimintakatsaus 16.1. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenWhy is it plummeting today?I think there is a fear of additional NE after today's webcast. Both CEO and CFO became very defensive when questions came up about how Glioblastoma studies would be financed. https://oncopeptides.com/press-releases/invitation-to-oncopeptides-investor-webcast-following-positive-glioblastoma-data/
- ·6 t sittenMay I please reiterate that one gets extra lifespan when other treatment options have ended. Oncopeptides has achieved an important regulatory breakthrough after EMA's expert committee in September 2026 recommended expanding the use of Melflufen (Pepaxti) to an earlier line of treatment in relapsed myeloma. According to the company, the expansion could potentially double the European patient group and thereby create the basis for significant revenue growth. Melflufen has documented anti-tumor effect, and the OCEAN study showed a median progression-free survival of 6.8 months compared to 4.9 months with pomalidomide. However, the study did not show an overall survival benefit, which continues to be a significant clinical limitation.
- ·1 päivä sittenThere are significant doubts and challenges surrounding melflufen in solid tumors. Although the latest results for brain tumors (glioblastoma) represent an important scientific advance, the medical community is generally cautious. The main doubts and challenges can be divided into three areas: 1. Historically weak efficacy in clinical studies The biggest doubt is based on the fact that melflufen has already been tested in patients with advanced solid tumors (such as lung cancer and ovarian cancer) in a phase I/IIa study. The result there was very modest, as practically no tumors shrank. This has created widespread skepticism about using the drug as a broad treatment for common solid tumors. 2. Side damage to the bone marrow (Hematological toxicity) Melflufen is a so-called Peptide-Drug Conjugate (PDC) designed to seek out cells with high aminopeptidase levels (which tumor cells have). The problem is that melflufen in clinical studies has proven to be very tough on the bone marrow, leading to severe shortages of platelets (thrombocytopenia) and white blood cells (neutropenia). * The doubt: For melflufen to affect a solid tumor, high doses are often required. Physicians worry that the doses needed to actually shrink a solid tumor may cause such severe blood side effects that the patient cannot tolerate the treatment. 3. "Proof of Concept" in humans is required for glioblastoma The new successes from the INSULA study prove that melflufen crosses into the brain and reaches the tumor (which is a huge step). But the drug being present in the tumor is not the same as it automatically curing or prolonging the lives of patients. Experts emphasize that we are still only at an early stage, and there is doubt (or rather, scientific uncertainty) as to whether the concentration is high enough to provide a long-lasting clinical effect against such an aggressive form of cancer as glioblastoma. The history haunts us (the OCEAN study in the US)
- ·2 päivää sittenI am down -97 percent on this stock 🥶I identified an entry point at the red dashed line five trading days ago, and bought 40000 shares this morning at 2.03. Have captured pretty much the entire day's upward move, corresponding to almost +45%, just saying it 😂😂
- ·2 päivää sittenHere we go, we should probably reach 10 kr if the flexibility process handling is fully met and they get a solid hit to eventually gain traction in the US via FDA approval.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 614 | - | - | ||
| 1 099 | - | - | ||
| 1 152 | - | - | ||
| 4 000 | - | - | ||
| 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 580 188 | 25 580 188 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 25 580 188 | 25 580 188 | 0 | 0 |